The impact of caffeine in inflammatory bowel disease: a review of the literature

Abstract

This review goes over the impact of caffeine consumption in inflammatory bowel disease (IBD), examining epidemiology, clinical outcomes, mechanistic studies, and translational research. Caffeine, a widely consumed methylxanthine, exerts diverse physiological effects on the gastrointestinal tract. Mechanistic and preclinical data offer plausible biological pathways by which caffeine could influence the IBD course. Caffeine’s antagonism of adenosine receptors may modulate immune cell activation and cytokine release; its effects on gut motility and secretion can alter symptom perception, and caffeine-mediated changes in intestinal epithelial barrier function, oxidative stress, and the gut microbiome have been demonstrated. These effects make it a lucrative investigational option, and various studies have demonstrated that caffeine intake may reduce the incidence of IBD and may even have disease-modifying effects in regular consumers. However, differences in caffeine source (coffee, tea, soda), dose, concurrent dietary patterns, and disease subtype (Crohn’s disease versus ulcerative colitis) limit definitive causal inference. Clinical implications remain cautious: while moderate caffeine intake may be tolerable and even helpful for many patients, individualized assessment is advisable, particularly for those with symptom-triggering sensitivity or overlapping functional bowel disorders. Future research should target mechanistic links and clinically meaningful outcomes to inform evidence-based dietary guidance for people with IBD.

Keywords

inflammatory bowel disease / ulcerative colitis / Crohn’s disease / caffeine / nutrition

References

[1] Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017; 390: 2769-78.

[2] Hracs L, Windsor JW, Gorospe J, Cummings M, Coward S, Buie MJ, et al.; Global IBD Visualization of Epidemiology Studies in the 21st Century (GIVES-21) Research Group. Global evolution of inflammatory bowel disease across epidemiologic stages. Nature. 2025; 642: 458-66.

[3] Wang R, Li Z, Liu S, Zhang D. Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019. BMJ Open. 2023; 13:e065186.

[4] Mokhtar NM, Nawawi KNM, Verasingam J, Zhiqin W, Sagap I, Azman ZAM, et al. A four-decade analysis of the incidence trends, sociodemographic and clinical characteristics of inflammatory bowel disease patients at single tertiary centre, Kuala Lumpur, Malaysia. BMC Public Health. 2019; 19: 550.

[5] Prideaux L, Kamm MA, De Cruz PP, Chan FKL, Ng SC. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol. 2012; 27: 1266-80.

[6] Watermeyer G, Awuku Y, Fredericks E, Epstein D, Setshedi M, Devani S, et al.; Gastroenterology and Hepatology Association of sub-Saharan Africa (GHASSA). Challenges in the management of inflammatory bowel disease in sub-Saharan Africa. Lancet Gastroenterol Hepatol. 2022; 7: 962-72.

[7] Singh S, Qian AS, Nguyen NH, Ho SKM, Luo J, Jairath V, et al. Trends in U.S. Health Care Spending on Inflammatory Bowel Diseases, 1996-2016. Inflamm Bowel Dis. 2022; 28: 364-72.

[8] Ghosh N, Premchand P. A UK cost of care model for inflammatory bowel disease. Frontline Gastroenterol. 2015; 6: 169-74.

[9] Kaplan GG, Ng SC. Understanding and Preventing the Global Increase of Inflammatory Bowel Disease. Gastroenterology. 2017; 152: 313-21.e2.

[10] Svolos V, Gordon H, Lomer MCE, Aloi M, Bancil A, Day AS, et al. European Crohn’s and Colitis Organisation consensus on dietary management of inflammatory bowel disease. J Crohns Colitis. 2025; 19: jjaf122.

[11] Nehlig A. Effects of Coffee on the Gastro-Intestinal Tract: A Narrative Review and Literature Update. Nutrients. 2022; 14: 399.

[12] Liszt KI, Ley JP, Lieder B, Behrens M, Stöger V, Reiner A, et al. Caffeine induces gastric acid secretion via bitter taste signaling in gastric parietal cells. Proc Natl Acad Sci U S A. 2017; 114: E6260-9.

[13] Jaquet M, Rochat I, Moulin J, Cavin C, Bibiloni R. Impact of coffee consumption on the gut microbiota: a human volunteer study. Int J Food Microbiol. 2009; 130: 117-21.

[14] Hwang C, Ross V, Mahadevan U. Popular exclusionary diets for inflammatory bowel disease: the search for a dietary culprit. Inflamm Bowel Dis. 2014; 20: 732-41.

[15] Sakamoto N, Kono S, Wakai K, Fukuda Y, Satomi M, Shimoyama T, et al.; Epidemiology Group of the Research Committee on Inflammatory Bowel Disease in Japan. Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm Bowel Dis. 2005; 11: 154-63.

[16] Meyer A, Dong C, Casagrande C, Chan SSM, Huybrechts I, Nicolas G, et al. Food Processing and Risk of Crohn’s Disease and Ulcerative Colitis: A European Prospective Cohort Study. Clin Gastroenterol Hepatol. 2023; 21: 1607-16.e6.

[17] Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol. 2011; 106: 563-73.

[18] Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017; 389: 1756-70.

[19] Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017; 389: 1741-55.

[20] Le Berre C, Ananthakrishnan AN, Danese S, Singh S, Peyrin-Biroulet L. Ulcerative Colitis and Crohn’s Disease Have Similar Burden and Goals for Treatment. Clin Gastroenterol Hepatol. 2020; 18: 14-23.

[21] Ray K. IBD: The changing epidemiology of IBD. Nat Rev Gastroenterol Hepatol. 2017; 14: 690.

[22] Martens EC, Neumann M, Desai MS. Interactions of commensal and pathogenic microorganisms with the intestinal mucosal barrier. Nat Rev Microbiol. 2018; 16: 457-70.

[23] Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009; 9: 799-809.

[24] He JS, Tan JY, Li XZ, Feng R, Xiong SS, Lin SN, et al. Serum biomarkers of fibrostenotic Crohn’s disease: Where are we now? J Dig Dis. 2020; 21: 336-41.

[25] Sato Y, Tsujinaka S, Miura T, Kitamura Y, Suzuki H, Shibata C. Inflammatory Bowel Disease and Colorectal Cancer: Epidemiology, Etiology, Surveillance, and Management. Cancers (Basel). 2023; 15: 4154.

[26] Michielan A, D’Incà R. Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut. Mediators Inflamm. 2015; 2015: 628157.

[27] Colgan SP, Fennimore B, Ehrentraut SF. Adenosine and gastrointestinal inflammation. J Mol Med (Berl). 2013; 91: 157-64.

[28] Lloyd-Price J, Arze C, Ananthakrishnan AN, Schirmer M, Avila-Pacheco J, Poon TW, et al.; IBDMDB Investigators; Braun J, Denson LA, Jansson JK, Knight R, Kugathasan S, McGovern DPB, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019; 569: 655-62.

[29] Yao S, Zhao Z, Wang W, Liu X. Bifidobacterium Longum: Protection against Inflammatory Bowel Disease. J Immunol Res. 2021; 2021: 8030297.

[30] Sun Y, Zhang Z, Zheng CQ, Sang LX. Mucosal lesions of the upper gastrointestinal tract in patients with ulcerative colitis: A review. World J Gastroenterol. 2021; 27: 2963-78.

[31] Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015; 21: 1982-92.

[32] Wangchuk P, Yeshi K, Loukas A. Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments. Trends Pharmacol Sci. 2024; 45: 892-903.

[33] Srinivasan AR. Treat to target in Crohn’s disease: A practical guide for clinicians. World J Gastroenterol. 2024; 30: 50-69.

[34] Kumar A, Smith PJ. Horizon scanning: new and future therapies in the management of inflammatory bowel disease. eGastroenterology. 2023; 1: e100012.

[35] Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015; 12: 205-17.

[36] Cosier D, Lambert K, Charlton K, Batterham M, Little RD, Wu N, et al.; On Behalf Of The Australian Ibd Microbiome Study Consortium; Hold GL. Dietary Patterns and Fibre Intake Are Associated with Disease Activity in Australian Adults with Inflammatory Bowel Disease: An Exploratory Dietary Pattern Analysis. Nutrients. 2024; 16: 4349.

[37] Iriondo-DeHond A, Uranga JA, Del Castillo MD, Abalo R. Effects of Coffee and Its Components on the Gastrointestinal Tract and the Brain-Gut Axis. Nutrients. 2020; 13: 88.

[38] Fulgoni VL 3rd, Keast DR, Lieberman HR. Trends in intake and sources of caffeine in the diets of US adults: 2001-2010. Am J Clin Nutr. 2015; 101: 1081-7.

[39] Mizoguchi E, Sadanaga T, Okada T, Minagawa T, Akiba J. Does caffeine have a double-edged sword role in inflammation and carcinogenesis in the colon? Intest Res. 2023; 21: 306-17.

[40] Stepanova M, Aherne CM. Adenosine in Intestinal Epithelial Barrier Function. Cells. 2024; 13: 381.

[41] Reddy VS, Shiva S, Manikantan S, Ramakrishna S. Pharmacology of caffeine and its effects on the human body. Eur J Med Chem Rep. 2024; 10: 100138.

[42] Lee IA, Kamba A, Low D, Mizoguchi E. Novel methylxanthine derivative-mediated anti-inflammatory effects in inflammatory bowel disease. World J Gastroenterol. 2014; 20: 1127-38.

[43] Zielińska D, Zieliński H, Laparra-Llopis JM, Szawara-Nowak D, Honke J, Giménez-Bastida JA. Caffeic Acid Modulates Processes Associated with Intestinal Inflammation. Nutrients. 2021; 13: 554.

[44] Kulokiene U, Inciuraite R, Butaite G, Salteniene V, Kiudelis V, Jonaitis LV, et al. P0221 The role of caffeine and its metabolites in the modulation of intestinal inflammation and epithelial barrier integrity. J Crohns Colitis. 2025; 19: i635.

[45] Mizoguchi E. Chitinase 3-like-1 exacerbates intestinal inflammation by enhancing bacterial adhesion and invasion in colonic epithelial cells. Gastroenterology. 2006; 130: 398-411.

[46] Cornelis MC, Gustafsson S, Ärnlöv J, Elmståhl S, Söderberg S, Sundström J, et al. Targeted proteomic analysis of habitual coffee consumption. J Intern Med. 2018; 283: 200-11.

[47] Dai A, Hoffman K, Xu AA, Gurwara S, White DL, Kanwal F, et al. The Association between Caffeine Intake and the Colonic Mucosa-Associated Gut Microbiota in Humans-A Preliminary Investigation. Nutrients. 2023; 15: 1747.

[48] Wang YF, Ou-Yang Q, Xia B, Liu LN, Gu F, Zhou KF, et al. Multicenter case-control study of the risk factors for ulcerative colitis in China. World J Gastroenterol. 2013; 19: 1827-33.

[49] Neamți L, Gheorghe SR, Ventuneac A, Drugan T, Drugan C, Silaghi CN, et al. Impact of Coffee Consumption on Subjective Perception and Inflammatory Markers in Patients with Inflammatory Bowel Diseases. Biomedicines. 2024; 12: 1733.

[50] Lawson PA, Saavedra Perez L, Sankaranarayanan K. Reclassification of Clostridium cocleatum, Clostridium ramosum, Clostridium spiroforme and Clostridium saccharogumia as Thomasclavelia cocleata gen. nov., comb. nov., Thomasclavelia ramosa comb. nov., gen. nov., Thomasclavelia spiroformis comb. nov. and Thomasclavelia saccharogumia comb. nov. Int J Syst Evol Microbiol. 2023; 73: 005694.

[51] Castaldo L, Toriello M, Sessa R, Izzo L, Lombardi S, Narváez A, et al. Antioxidant and Anti-Inflammatory Activity of Coffee Brew Evaluated after Simulated Gastrointestinal Digestion. Nutrients. 2021; 13: 4368.

[52] Sun M, Wu W, Liu Z, Cong Y. Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases. J Gastroenterol. 2017; 52: 1-8.

[53] Nakayama T, Oishi K. Influence of coffee (Coffea arabica) and galacto-oligosaccharide consumption on intestinal microbiota and the host responses. FEMS Microbiol Lett. 2013; 343: 161-8.

[54] Saygili S, Hegde S, Shi XZ. Effects of Coffee on Gut Microbiota and Bowel Functions in Health and Diseases: A Literature Review. Nutrients. 2024; 16: 3155.

[55] Rao SS, Welcher K, Zimmerman B, Stumbo P. Is coffee a colonic stimulant? Eur J Gastroenterol Hepatol. 1998; 10: 113-8.

[56] Boekema PJ, Samsom M, van Berge Henegouwen GP, Smout AJ. Coffee and gastrointestinal function: facts and fiction. A review. Scand J Gastroenterol Suppl. 1999; 230: 35-9.

[57] Brown SR, Cann PA, Read NW. Effect of coffee on distal colon function. Gut. 1990; 31: 450-3.

[58] Lu YT, Gunathilake M, Lee J, Kim Y, Oh JH, Chang HJ, et al. Coffee consumption and its interaction with the genetic variant AhR rs2066853 in colorectal cancer risk: a case-control study in Korea. Carcinogenesis. 2022; 43: 203-16.

[59] Shojaei-Zarghani S, Yari Khosroushahi A, Rafraf M, Asghari-Jafarabadi M, Azami-Aghdash S. Dietary natural methylxanthines and colorectal cancer: a systematic review and meta-analysis. Food Funct. 2020; 11: 10290-305.

[60] Yang X, Yan H, Chen Y, Guo R. Association Between Caffeine Intake and Bowel Habits and Inflammatory Bowel Disease: A Population-Based Study. J Multidiscip Healthc. 2025; 18: 3717-26.

[61] Barthel C, Wiegand S, Scharl S, Scharl M, Frei P, Vavricka SR, et al. Patients’ perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe?-a patient survey. Nutr J. 2015; 14: 78.

[62] Almofarreh A, Sheerah HA, Arafa A, Ahamed SS, Alzeer O, Al-Hunaishi W, et al. Beverage Consumption and Ulcerative Colitis: A Case-Control Study from Saudi Arabia. Int J Environ Res Public Health. 2022; 19: 2287.

[63] Qin L, Lv W. Dietary content and eating behavior in ulcerative colitis: a narrative review and future perspective. Nutr J. 2025; 24: 12.

[64] Nie JY, Zhao Q. Beverage consumption and risk of ulcerative colitis: Systematic review and meta-analysis of epidemiological studies. Medicine (Baltimore). 2017; 96: e9070.

[65] Tanaka K, Okubo H, Miyake Y, Nagata C, Furukawa S, Andoh A, et al.; Japan Ulcerative Colitis Study Group. Coffee and caffeine intake reduces risk of ulcerative colitis: a case-control study in Japan. J Gastroenterol Hepatol. 2024; 39: 512-8.

[66] Persson PG, Ahlbom A, Hellers G. Diet and inflammatory bowel disease: a case-control study. Epidemiology. 1992; 3: 47-52.

[67] Dong H, Xu F, Linghu E. Unraveling the link between plasma caffeine concentrations and inflammatory bowel disease risk through Mendelian randomization. Am J Clin Nutr. 2024; 119: 711-5.

[68] Feagins LA, Melton SD, Iqbal R, Dunbar KB, Spechler SJ. Clinical implications of histologic abnormalities in colonic biopsy specimens from patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis. 2013; 19: 1477-82.

[69] de Jong MJ, Roosen D, Degens JHRJ, van den Heuvel TRA, Romberg-Camps M, Hameeteman W, et al. Development and Validation of a Patient-reported Score to Screen for Mucosal Inflammation in Inflammatory Bowel Disease. J Crohns Colitis. 2019; 13: 555-63.

[70] Melones-Peña N, Gómez-Gómez B, Gracia-Lor E. How much consumed caffeine is actually absorbed? Bioaccessibility and bioavailability in energy drinks, infusions and soft drinks. Food Chem. 2025; 492: 145626.

[71] Ng SC, Tang W, Leong RW, Chen M, Ko Y, Studd C, et al.; Asia-Pacific Crohn’s and Colitis Epidemiology Study ACCESS Group. Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific. Gut. 2015; 64: 1063-71.

[72] Rizzello F, Spisni E, Giovanardi E, Imbesi V, Salice M, Alvisi P, et al. Implications of the Westernized Diet in the Onset and Progression of IBD. Nutrients. 2019; 11: 1033.

[73] Georgiou AN, Ntritsos G, Papadimitriou N, Dimou N, Evangelou E. Cigarette Smoking, Coffee Consumption, Alcohol Intake, and Risk of Crohn’s Disease and Ulcerative Colitis: A Mendelian Randomization Study. Inflamm Bowel Dis. 2021; 27: 162-8.

[74] Wang K, Li Z, He J. Association of caffeine consumption with all-cause and cause-specific mortality in adult Americans with hypertension. Food Sci Nutr. 2024; 12: 4185-95.